Immuno-polymeric Drugs For Prostate Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$626,995.00
Summary
Prostate cancer is the most common cancer in men over 50 and the second most frequent cause of cancer deaths in Western society. Docetaxel is the first line of chemotherapy when other intervention strategies are unsuccessful, but 30% of patients suffer from severe side-effects. To address this problem, we will utilise carriers for docetaxel that directly target prostate tumours using a novel antibody approach. This increases accumulation at the tumour site while decreasing off-target toxicity.
Identification Of Germline Variation That Predicts Progression Free Survival Following Chemotherapy For Advanced Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$633,156.00
Summary
Women diagnosed with ovarian cancer typically undergo surgery, followed by chemotherapy. However, the efficacy of chemotherapy varies widely, with some women responding well, whilst others are exposed to the toxic effects of a treatment that does them little good. We aim to identify the genes which explain why there are differences in response. This will lead to more individualised chemotherapy and improved outcomes for women with ovarian cancer.
Pharmacology Of Potential Anti-Tumour Agents: Iron Chelators Of The BpT Class
Funder
National Health and Medical Research Council
Funding Amount
$585,455.00
Summary
Pharmacology of Potential Anti-Tumour Agents: Iron Chelators of the BpT Class Cancer cells have a high iron requirement for DNA synthesis and many clinical trials showed Fe chelators are effective anti-cancer drugs. Their potential to act as anti-tumour agents has been confirmed by the entrance of Triapine into widespread NCI clinical trials. In this NHMRC Renewal, we will perform pharmacological and preclinical studies to promote the development of BpT chelators as novel anti-tumour agents.
An Investigation Of The Involvement Of Clotting Factors In Abdominal Aortic Aneurysm (AAA) Progression Within A Mouse Model
Funder
National Health and Medical Research Council
Funding Amount
$189,401.00
Summary
Early stage weakening of the main abdominal artery is present in ~100,000 Australians and currently has no accepted therapy. Development of drug therapies which limit progression of the weakening process is urgently needed. In this study involvement of the clotting cascade in artery weakening will be investigated. The study have been planned in order to identify new strategies which can be developed as treatments for artery weakening in patients.
Improving Sexual Health In Men With Prostate Cancer: Randomised Controlled Trial Of Exercise And Psychosexual Therapies
Funder
National Health and Medical Research Council
Funding Amount
$583,416.00
Summary
Sexual dysfunction is one of the most common and distressing side effects of prostate cancer. Despite being a critical survivorship care issue, there is a clear gap in knowledge surrounding the optimal treatment of sexual dysfunction in men with prostate cancer. This project examines whether exercise aids in the management of sexual dysfunction and explores if an integrated treatment model incorporating pharmacological, exercise and psychosexual therapies maximises improvement in sexual health.
Caged lanthanides for use in photo-dynamic therapy and near infra-red imaging. The early detection and effective treatment of cancer are two critical factors which determine survivability. This project will provide improved drugs for photo-dynamic therapy and develop emissive probes for near infra-red imaging to allow better discrimination between healthy and diseased tissue and improve subsequent treatment.
Microfluidic Strategy For Circulating Tumour Cells Analysis In Cancer Patients
Funder
National Health and Medical Research Council
Funding Amount
$429,180.00
Summary
My approach and ultimate goal over the next 4 years is to demonstrate the use of recently discovered “Nanoshearing” technology as a standard diagnostic tool for cancer patients undergoing systemic therapy and assess the impact of standard protocols in predicting response to therapy and patient outcomes. Data from this study could potentially define new standards of clinical practice, as they relate to follow-up screening for response to therapy and recurrence of disease.
Pathways To Mental Health And Obesity In Young Adults: A Longitudinal Study
Funder
National Health and Medical Research Council
Funding Amount
$698,510.00
Summary
While the health of the population has been gradually improving, there are some health problems which are increasing. The mental health of young people is one such area. Based on data relating to youth suicide, substance abuse, cigarette smoking by females and behavioural or mental health problems in the young, there has been evidence of a marked increase in some important health problems faced by the young. Little is known about the causes of these problems and even less is known about the reas ....While the health of the population has been gradually improving, there are some health problems which are increasing. The mental health of young people is one such area. Based on data relating to youth suicide, substance abuse, cigarette smoking by females and behavioural or mental health problems in the young, there has been evidence of a marked increase in some important health problems faced by the young. Little is known about the causes of these problems and even less is known about the reasons for the increase. Based on the available evidence, 20-25% of young persons manifest a mental health problem. A second area of marked health deterioration concerns youth (and adult) obesity. Existing research points to the accumulation of cardiovascular risk factors associated with obesity from a very early age. Over 10% of youth are obese and a substantially higher proportion are overweight. There is evidence that the rate of obesity has been substantially increasing. Again little is known about the factors that contribute to obesity or the causes of the increase in the rates of obesity in the population. This proposal is for a 21-year follow-up of a sample of youth first enrolled when their mothers attended for their first obstetrical visit. Using a substantial body of existing data, we propose to examine the changes in levels of mental health and obesity and to identify the factors which contribute to these changes. This study involves the largest Australian cohort ever assembled for such research. The main questions asked in this study concern the impact of the mother's social and economic circumstances, her physical health and well-being, her use of addictive substances (including alcohol, cigarettes, illicit drugs) on the youth's health. We will also examine the association between early indicators of mental health and well-being and subsequent youth health and development.Read moreRead less
Which Modifiable Risk Factors Actually Cause Cancer?
Funder
National Health and Medical Research Council
Funding Amount
$384,076.00
Summary
Observational studies suggest that modifiable risk factors such as low vitamin D levels, coffee consumption, alcohol consumption and obesity may be important in cancer risk. However, observational studies can only demonstrate association between a risk factor and cancer, and association does not equal causation. We present an alternative approach to help determine which risk factors actually cause cancer.
EGFR-directed radioimmunotherapy combined with chemotherapy and DNA repair inhibition: development towards clinical application for aggressive cancers. Pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer (TNBC) are aggressive diseases which lack effective therapies in clinical use. A novel and curative therapy was developed against PDAC and TNBC which involves targeted radiotherapy combined with chemotherapy and DNA damage response inhibition. This project will develop a “p ....EGFR-directed radioimmunotherapy combined with chemotherapy and DNA repair inhibition: development towards clinical application for aggressive cancers. Pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer (TNBC) are aggressive diseases which lack effective therapies in clinical use. A novel and curative therapy was developed against PDAC and TNBC which involves targeted radiotherapy combined with chemotherapy and DNA damage response inhibition. This project will develop a “preclinical data package” comprising a biological rationale and preclinical evidence of safety and efficacy that together would justify an early phase clinical trial. This package includes the choice of formulations, mechanism of action and safety studies. This development will have an immediate impact for PDAC and TNBC patients and a future impact on other EGFR-positive cancers.Read moreRead less